Fate Therapeutics, Inc. (FATE) News

Latest headlines that mention FATE, newest first · each headline opens the original publisher

FATE quote

Last price: $1.94
Day change: +5.72%
Next earnings: —

Quote & chart Expected move Insider trading IV rank history

FATE headlines

latest coverage

Seeking Alpha 4d ago

Fate Therapeutics GAAP EPS of -$0.25 beats by $0.02

Earnings T2FATE

Investing.com 1mo ago

Fate Therapeutics receives $15m CIRM grant for lupus trial

General T3FATE

Investing.com 2mo ago

Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances

General T3FATE

Investing.com 2mo ago

Fate Therapeutics presents FT819 lupus trial data at conference

General T3FATE

Seeking Alpha News 2mo ago

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

General T2FATE

Investing.com 2mo ago

Fate Therapeutics earnings beat by $0.02, revenue topped estimates

Earnings T3FATE

Seeking Alpha 2mo ago

Fate Therapeutics GAAP EPS of -$0.25 beats by $0.02, revenue of $2.08M beats by $0.81M

Earnings T2FATE

Seeking Alpha News 4mo ago

Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade)

General T2FATE

Seeking Alpha News 4mo ago

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

General T2FATE

Investing.com 5mo ago

Form 144 FATE THERAPEUTICS INC For: 20 May

General T3FATE

Investing.com 6mo ago

Fate Therapeutics earnings beat by $0.02, revenue topped estimates

Earnings T3FATE

FATE news alerts

Get an alert by email or push when a new headline mentions FATE.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.